ArticleBritish journal of haematology2019
Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.
Article in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04676113 (Obesity in Pediatric Sickle Cell Disease), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Obesity in Pediatric Sickle Cell Disease: A New Phenomenon
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis.Orphanet journal of rare diseases · 2026Article
- Adiponectin levels during steady state and vaso-occlusive crisis in Nigerian children with sickle cell anaemia.Annals of hematology · 2026Article
- Article
- Hemoglobin S Promotes Glycemic Dysregulation in a Mouse Model of Human Sickle Cell Disease.Endocrinology · 2025Article
- Intracranial aneurysms in sickle cell disease are associated with hemodynamic stress and anemia.Blood advances · 2024Article
- GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.American journal of hematology · 2024Article
- Diabetes Screening Rates and Practices in Patients With Sickle Cell Disease.Diabetes care · 2024Article
- Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?International journal of molecular sciences · 2023Review
- Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence.Acta bio-medica : Atenei Parmensis · 2022Review
- Rare occurrence of type 2 diabetes mellitus in patients with sickle cell anaemia: assessing the contribution of inflammation, insulin resistance and glucose buffering capacity of abnormal haemoglobin.Journal of medical science · 2022Article
- Article
- Hemoglobin APediatric blood & cancer · 2020Article
- Increased iron stores influence glucose metabolism in sickle cell anaemia.British journal of haematology · 2020Article
- Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.Heart (British Cardiac Society) · 2020Review
- Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus.Blood advances · 2019Article
- Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series.Obesity surgery · 2019Article
- Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al.British journal of haematology · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
Conflicting evidence exists on the epidemiology of type 2 diabetes mellitus (T2DM) among patients with sickle cell disease (SCD). This study measured the prevalence, incidence and clinical outcomes associated with T2DM in a large US population of commercially-insured adults aged ≥20 years with SCD between 2009 and 2014. Among 7070 patients with SCD, the mean age (median) was 39 (37) years and 60·8% were female. The standardized prevalence of T2DM among patients with SCD showed a modest increase, from 15·7% to 16·5% (P trend = 0·026), and was comparable to African-American respondents to the National Health and Nutrition Examination Survey (18·2%). Over 17 024 person-years, the crude incidence rate for T2DM was 25·4 per 1000 person-years. Incident T2DM was associated with comorbid hypertension (hazard ratio [HR] = 1·45, 95% confidence interval [CI] 1·14-1·83), and dyslipidaemia (HR = 1·43, 95%CI 1·04-1·96). Compared to SCD patients without T2DM, more SCD patients with T2DM had diagnoses of nephropathy (28·0% vs. 9·5%; P < 0·001), neuropathy (17·7% vs. 5·2%; P < 0·001) and stroke (24·1% vs. 9·2%; P < 0·001). Prevalence of T2DM in SCD patients is similar to the general African American population with an increasing trend in recent years. These trends support routine screening for T2DM in aging patients with SCD, especially those with comorbid hypertension and/or dyslipidaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.